---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-24-000082"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:00:27.312880+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q3 2024 revenue $20.4M (+15% YoY), net loss $14.1M

## Summary
- Worldwide revenue $20.4M, up 15% YoY; U.S. revenue $13.8M (+17% YoY); international $6.6M (+12%).
- Gross margin 74% unchanged YoY; net loss $14.1M ($0.36 loss per share) vs $14.9M ($0.39) in Q3 2023.
- Adjusted EBITDA loss $8.1M vs $9.0M in Q3 2023; cash & marketable securities $107.8M as of Sep 30.
- Full-year 2024 revenue guidance reaffirmed $81M-$84M; op ex guidance narrowed to $122M-$124M.
- Added 15 new Zephyr Valve U.S. treatment centers; AeriSeal CONVERT trial showed 77.6% conversion rate.

## SEC filing metadata
- accession: 0001127537-24-000082
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000082/0001127537-24-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000082/lung-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-24-000082
- JSON: https://secwatch.observer/filing/0001127537-24-000082.json
- Plain text: https://secwatch.observer/filing/0001127537-24-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.